Alzheimer’s and Parkinson’s disease research presented by Revalesio at national scientific conference
Date: March 14, 2011
TACOMA, Wash. – Revalesio Corporation and Rush University will present research on the use of RNS60 at the American Society of Neurochemistry (ASN) meeting in St. Louis.
Researchers at Rush University Medical Center demonstrated profound anti-inflammatory activity of RNS60, a biologically active fluid possessing charge-stabilized nanostructures (CSN), in models of Alzheimer’s and Parkinson’s diseases. These findings establish RNS60 as a strong candidate for further development as a novel therapeutic in neurodegenerative diseases.
The ASN’s annual conference, scheduled for March 16-18, brings together molecular and cellular neuroscientists to share the latest research and advance the field of neurology.
RNS60 demonstrates “protective” effect in Alzheimer’s disease and Parkinson’s disease
Research conducted at Rush University revealed that RNS60 protected cultured cells against beta amyloid-induced cell death, a known driver of Alzheimer’s disease. Since RNS60 is unique in its anti-inflammatory activity, these results identify a novel approach to inhibiting neuronal damage from beta amyloid and potentially a new approach for treating Alzheimer’s disease. Revalesio will present further research demonstrating the prevention of tau hyperphosphorylation – another key factor in the progression of Alzheimer’s disease – at the American Academy of Neurology meeting April 9-16 in Honolulu, HI.
At the ASN conference, Revalesio will also present data related to Parkinson’s disease. In a neurotoxin model of the disease, RNS60 protected neurons, restored dopamine levels, and improved the motor function of Parkinson’s affected mice. These results suggest a potential therapeutic benefit of RNS60 for patients suffering from Parkinson’s disease.
About charge-stabilized nanostructures (CSN)
Revalesio has pioneered the novel use of charge-stabilized nanostructures to alter whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the expression of G protein-coupled receptors and the secretion of cytokines, chemokines and adhesion molecules. These changes to whole cell conductance reduce inflammatory signals that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.
About Revalesio Corporation:
Revalesio is a pioneering biotechnology company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is pioneering the use of CSN in neuro-inflammatory, respiratory, cardiovascular, and other inflammatory diseases. For more information, please visit: revalesio.com.